Dr. David Roblin, MBBS FMedSci is The Chief Operating Officer at Juvenescence. He is also the CEO of the JuvTherapeutics division.

David is a distinguished scientist and physician who practiced medicine in London before joining Pfizer and Bayer where he led European R&D and developed medicines including ciprofloxacin, moxifloxacin, maraviroc and sildenafil. He has also experience as Board director and in the C-suite of biotech, moving his companies forward and raising money from private and public markets.

Dr. Roblin has a unique line of sight from academia to industry and patients and was the first COO and director of scientific translation at the Francis Crick Institute in London. He co-founded the Innovative Medicines Initiative, a €2Bn public private partnership in pre-competitive science with the European Union.